Cancer is the second leading cause of death worldwide. Despite the availability of numerous therapeutic options, tumor heterogeneity and chemoresistance have limited the success of these treatments, and the development of effective anticancer therapies remains a major focus in oncology research. The serine/threonine-protein phosphatase 1 (PP1) and its complexes have been recognized as potential drug targets. Research on the modulation of PP1 complexes is currently at an early stage, but has immense potential. Chemically diverse compounds have been developed to disrupt or stabilize different PP1 complexes in various cancer types, with the objective of inhibiting disease progression. Beneficial results obtained in vitro now require further pre-clinical and clinical validation. In conclusion, the modulation of PP1 complexes seems to be a promising, albeit challenging, therapeutic strategy for cancer.

癌症是全球第二大死亡原因。尽管有许多治疗选择，但肿瘤异质性和化学抗性限制了这些治疗的成功，而开发有效的抗癌疗法仍然是肿瘤学研究的主要焦点。丝氨酸/苏氨酸蛋白磷酸酶 1 (PP1) 及其复合物已被认为是潜在的药物靶点。PP1复合物调控的研究目前处于早期阶段，但潜力巨大。已经开发出化学上多样化的化合物来破坏或稳定各种癌症类型中的不同 PP1 复合物，目的是抑制疾病进展。体外获得的有益结果现在需要进一步的临床前和临床验证。总之，PP1 复合物的调节似乎是一种有前途但具有挑战性的癌症治疗策略。